GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Is an In-House Cell Lab Better?

Not automatically. An in-house cell lab may simplify scheduling and reduce transport between sites. An outside facility may be a better option if it can demonstrate stronger processing controls for the proposed cells. Neither location alone proves that treatment is safer or more effective. Compare the actual facility, batch-release checks, and human evidence for your condition—not the address.

If you are comparing clinics in Japan, ask which exact cell processing center will handle your cells. Japan distinguishes notification, permission, and certification routes for facilities under its regenerative-medicine safety framework; the applicable route depends on the facility setting. Those routes concern processing oversight, not proof that one lab model produces better patient outcomes Manufacturiungfacility.

Is an In-House Cell Lab Better?

What Are You Comparing?

Here, in-house means processing takes place on the treatment premises. Outsourced means another facility performs some or all of the processing. Ownership is a separate question: a clinic group may own a distant facility, while an on-site laboratory may be run by a contractor. Ask for the processing address and operator, not just the word “in-house.”

Keep three decisions separate:

  • Processing: Can this site prepare, identify, store, and release the proposed cells under documented controls?
  • Clinical care: Who assesses your suitability, administers treatment, and handles complications?
  • Evidence: Does the proposed intervention have credible human evidence for your diagnosis, and what is its regulatory status?

A facility notification, permission, or certification helps establish its regulatory status under the relevant route. It does not rank the facility against competitors or prove clinical benefit. MHLW separately sets out facility requirements covering manufacturing equipment, quality management, personnel, and records Manufacturiungfacility.

When On-Site Processing May Help

If the proposed protocol has a short interval between collection and administration, processing on the same premises may avoid an inter-site shipment. Ask the clinician to explain the protocol’s time limit and how each option meets it. A shorter journey is a logistical advantage, not a sterility test.

On-site staff may also coordinate collection, receipt, and administration more easily. That advantage matters only if the laboratory has the required staff and controls available when your batch is processed. Sharing a building does not establish staff availability or the quality of the release decision.

Do not accept “same-day” as a reason to skip checks. Ask which results must be available before administration, which—if any—will arrive afterward, and what the team does if a later result is abnormal. The answer should be specific to the proposed product and protocol, rather than a promise that faster always means better.

When an Outside Facility May Help

An outside facility may be preferable if it can document relevant processing experience, suitable equipment, trained staff, and clearer quality oversight than the on-site alternative. These are points to verify, not qualities that outsourcing automatically provides. An in-house laboratory can also have dedicated staff and strong controls.

Ask both facilities who authorizes release and who can stop a batch from being used. Being employed by a separate company does not, by itself, establish independent quality review. Ask how disagreements between the clinician, processing team, and quality staff are resolved.

For an outside site, add transport questions: what containers, temperature range, time limit, identity checks, and arrival-acceptance criteria apply? Who acts if a shipment is delayed or arrives outside its specified conditions? Obtain a written explanation of responsibility across the clinic, laboratory, and courier.

Processing steps must also be compared like for like. Either setup may prepare cells for same-day use or grow them in culture, depending on its capabilities and the protocol. Do not assume that “outside facility” means expanded cells or that “in-house” means fresh cells.

Compare the Two Options

Questions to apply to the actual facilities, not assumptions about their location
Decision point In-house lab Outside facility
Movement of cells May avoid an inter-site shipment; internal identification and handover checks still matter. Ask for transport conditions, time limits, and documented arrival checks.
Staff and equipment Verify staffing during your processing period and equipment maintenance. Verify the same; a dedicated center’s name does not establish its capabilities.
Release decision Ask which criteria must pass and who can withhold the batch. Ask the same, including how results reach the treating clinician.
Processing steps Confirm whether cells are separated, cultured, frozen, or otherwise processed. Confirm the same steps before comparing timing or price.
Regulatory documents Match the site and operator to the applicable facility record. Match the actual processing site, not just the clinic or parent company.
Treatment evidence Ask for evidence matching the condition, cell source, processing, dose, and administration route. Facility location cannot answer whether the intervention works.

For costs, compare processing, testing, storage, transport, repeat collections, cancellation terms, and follow-up separately. A treatment cost breakdown is more useful than two headline prices covering different services.

What to Do During a Clinic Visit

If a clinic offers a laboratory tour, use it to ask about the process. Seeing a room or equipment cannot establish what happened to your batch. Ask for a patient-facing explanation of the processing site, release criteria, and evidence for the proposed treatment.

A Same-Day Scheduling Scenario

Suppose a clinic offers collection in the morning and administration that afternoon. Before paying, ask: “Which checks will be complete before administration? Who signs off the batch? What happens to my appointment and payment if it cannot be released?” This is a hypothetical decision scenario, not a reported patient case. A clear answer helps you assess the arrangement; it does not establish that the treatment is effective.

A Transport Delay Scenario

Suppose an outside laboratory’s shipment arrives after the agreed time limit. Ask who reviews the deviation, whether administration is postponed, and how you will be informed. Apply the same principle to an on-site equipment failure: the useful comparison is the written response to a problem, not the distance from the lab to the treatment room.

Ask for documents naming the exact facility that will handle your cells, including any subcontracted stage. If a certificate names a parent company or another address, ask the issuer or clinic to clarify its scope rather than assuming it covers your processing site.

Facility Status Is Not Treatment Approval

Check the proposed intervention before choosing either lab. FDA warns that unapproved regenerative-medicine products can cause serious harm, including infections, unwanted immune reactions, and tumor formation. That U.S. warning is not a determination about a particular Japanese clinic, but it explains why a laboratory’s appearance cannot settle the safety question Important patient and consumer information about regenerative medicine therapies.

In Japan, a service provided under a filed regenerative-medicine treatment plan is not equivalent to a marketed regenerative medical product approved for a specific indication. MHLW explains the separate frameworks, and PMDA provides approved-product information; neither should be read as blanket approval of all regenerative-medicine services Manufacturiungfacility 0002.

The United States has a similar registration-versus-approval distinction, although its rules are different. For establishments handling human cells, tissues, and cellular and tissue-based products regulated solely under section 361 and 21 CFR part 1271, FDA states that registration and listing are required within 5 days of beginning operation, with annual registration updates in December. FDA acceptance of registration and listing does not establish compliance or product approval Tissue establishment registration.

What a Documented Outbreak Shows

As of December 14, 2018, CDC had received reports of infections in 12 patients in Texas, Florida, and Arizona after administration of contaminated, unapproved umbilical cord blood-derived products. All 12 were hospitalized; none had died as of that report. Contamination was also found in unopened vials Mm6750a5.htm.

This was one outbreak, not a general complication rate or a comparison of in-house and outsourced laboratories. It illustrates why contamination controls matter; it cannot identify the safer lab model.

Questions Before You Consent

  • What is my diagnosis, and why is this intervention being proposed instead of established alternatives?
  • Are the cells my own or donor-derived, and what processing, dose, route, and number of sessions are planned?
  • Is this an approved treatment for this use, an experimental intervention, or a clinic service under another regulatory pathway?
  • What human studies match this use? Ask about study phase and design, sample size, comparison group, outcomes, follow-up, and adverse events—not just testimonials or a trial-registration number.
  • What batch information can I receive, and what happens if the cells do not meet release criteria?
  • Who provides follow-up and urgent care if a complication occurs after I leave?

Trial registration documents a study’s registration, not proof that treatment works. Evidence for another disease, cell preparation, or delivery route may not apply to your proposal. Review the treatment’s indications and contraindications with a qualified clinician, and seek an independent clinical opinion before committing.

Risks depend on the cells, processing, patient, and administration procedure. Possible harms of unapproved products include reactions at collection or administration sites, serious infection, and unintended tissue growth; treatment may also fail to help. These risks should not be presented as identical across all cell therapies or as eliminated by on-site processing Important patient and consumer information about regenerative medicine therapies.

Bottom Line

An in-house lab may offer simpler logistics. An outside facility may offer capabilities that a particular clinic lacks. Choose neither on that label alone: first establish whether the proposed treatment is appropriate, then compare the named sites’ controls, release decisions, and arrangements for problems. If either provider cannot explain those points, pause before paying.

This article provides general information, not personal medical advice or an inspection of any specific facility.

Have questions about the proposed processing facility?

Use the contact form to ask about the processing location and what information is available before deciding on next steps.

Ask a question